cetylpyridinium chloride
Small moleculeexperimental
Cetylpyridinium chloride (CPC) is a cationic quaternary ammonium compound used in some types of mouthwashes, toothpastes, lozenges, throat sprays, breath sprays, and nasal sprays. It is an antiseptic that kills bacteria and other microorganisms. It has been shown to be effective in preventing dental plaque and reducing gingivitis. It has also been used as an ingredient in certain pesticides. Though one study seems to indicate cetylpyridinium chloride does not cause brown tooth stains, at least one mouthwash containing CPC as an active ingredient bears the warning label "In some cases, antimicrobial rinses may cause surface staining to teeth," following a failed class-action lawsuit brought by customers whose teeth were stained. — Wikipedia
Clinical trial activity
39 trials · 47 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
17
Phase 3
9
Phase 4
7
Earliest trial started Jan 1, 2008 (NCT00687037)
Timeline
Indications
Approved for
Studied for
- Biofilms · Phase 1
- Common Cold · Phase 3
- Coronavirus · Phase 4
- Coronavirus Infections · Phase 2
- COVID-19 · Phase 4
- Dental Caries · Phase 4
- Dental Plaque · Phase 4
- Drug-Related Side Effects and Adverse Reactions · Phase 2
- Gingival Diseases · Phase 3
- Gingivitis · Phase 4
- Healthy Volunteers · Phase 3
- Hygiene · Phase 3
- Infant, Premature · Phase 2
- Mouthwashes · Phase 4
- Mucositis · Phase 2
- Nasopharyngitis · Phase 2
- Pain · Phase 3
- Periodontal Diseases · Phase 4
- Periodontitis · Phase 2
- Pharyngeal Diseases · Phase 2
- Pharyngitis · Phase 4
- Polymerase Chain Reaction · Phase 4
- Quadriceps Muscle · Early Phase 1
- Respiratory Tract Infections · Phase 2
- Saliva · Phase 4
- Sarcopenia · Early Phase 1
- SARS-CoV-2 · Phase 4
- Viral Load · Phase 4
- Virus Diseases · Phase 2
Mechanism of action
- Unspecified targetUnclear
unclear
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Loading structure…
SMILES
CCCCCCCCCCCCCCCC[n+]1ccccc1.O.[Cl-]- Mol. weight
- 358.01 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCetylpyridinium chloride ↗
- ChEMBLCHEMBL2003538 ↗
Also known as
- ceepryn
- ceepryn
- ceepryn
- cepacol
- cepacol
- cepacol
- cetylpyridinium chloride
- cetylpyridinium chloride
- cetylpyridinium chloride
- cetylpyridinium chloride
- cetylpyridinium chloride
- cetylpyridinium chloride hydrate
- cetylpyridinium chloride hydrate
- gppe dental rinse
- gppe oral liq
- merocet
- merocet
- merocets
- merocets
- merocets plus
- merovit
- search
- steradent
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06859281 | Phase 1 | Dec 10, 2024 | Valenta Pharm JSC |
| NCT06843018 | Phase 2 | Nov 14, 2024 | Valenta Pharm JSC |
| NCT06598072 | Phase 3 | Sep 17, 2024 | Colgate Palmolive, Universidad Autonoma de San Luis Potosi |
| NCT06607263 | Phase 3 | Sep 16, 2024 | Colgate Palmolive, Federal University of Rio Grande do Sul |
| NCT05802628 | Phase 4 | Apr 10, 2023 | Peking University |
| NCT06437262 | Phase 1 | Sep 1, 2022 | Lacer, S.A., University of Santiago de Compostela |
| NCT06479226 | Phase 3 | Jun 5, 2022 | Colgate Palmolive |
| NCT05178173 | N/A | Jan 20, 2022 | University of North Carolina at Chapel Hill |
| NCT05521230 | Phase 1 | Sep 1, 2021 | Lacer, S.A., University of Santiago de Compostela |
| NCT04902976 | N/A | Apr 4, 2021 | Albert Einstein Israelite Hospital, Colgate Palmolive, University of Sao Paulo |
| NCT04757818 | N/A | Feb 17, 2021 | Dentaid, FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA, IrsiCaixa |
| NCT04721457 | Phase 4 | Jan 3, 2021 | King Abdul-Aziz University |
| NCT04584684 | Phase 2 | Dec 31, 2020 | University of North Carolina at Chapel Hill |
| NCT04409873 | Phase 2 | Jul 1, 2020 | University of California, San Francisco |
| NCT04254835 | Phase 4 | Feb 1, 2020 | Cairo University |
| NCT05270382 | N/A | Feb 1, 2020 | University of Illinois at Chicago |
| NCT04308161 | Phase 2 | Nov 2, 2019 | Alexandria University |
| NCT04095442 | Early Phase 1 (Phase 1) | Oct 31, 2019 | Indiana University |
| NCT04317183 | Phase 2 | May 15, 2019 | Alexandria University |
| NCT03833570 | Phase 2 | Jan 12, 2018 | Alexandria University |
Showing 20 of 39 trials
Page 1 / 2
Organizations
Research & Development (47)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Colgate Palmolive | For profit | 7 | 6 | 3 | 2014 |
| Alexandria University | Academic/Hospital | 3 | 3 | 1 | 2018 |
| Lacer, S.A. | For profit | 2 | 0 | 1 | 2021 |
| Sanofi | For profit | 2 | 2 | 1 | 2008 |
| Sanofi-Aventis | For profit | 2 | 0 | 1 | 2008 |
| Seoul National University | Academic/Hospital | 2 | 2 | 1 | 2014 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 2 | 2 | 2 | 2020 |
| University of Santiago de Compostela | Academic/Hospital | 2 | 2 | 1 | 2021 |
| Valenta Pharm JSC | For profit | 2 | 2 | 2 | 2024 |
| Albert Einstein Israelite Hospital | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Angelini | For profit | 1 | 1 | 1 | 2017 |
| ARMS Pharmaceutical LLC | For profit | 1 | 0 | 1 | 2017 |
| Azad University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Bill and Melinda Gates Foundation | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Cairo University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Cross Research S.A. | For profit | 1 | 0 | 1 | 2017 |
| Dentaid | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Federal University of Rio Grande do Sul | Academic/Hospital | 1 | 0 | 1 | 2024 |
| FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Hebrew University | Academic/Hospital | 1 | 1 | 1 | 2009 |
47 organizations
Page 1 / 3